Table 3.
Phase-I-II-III studies with pegylated liposomal doxorubicin (PLD) in combination with target agents.
| Author | Dose/schedule | Clinical setting PFI (mts) |
No. pts | RR (%) | PFS (median) (mts) |
|---|---|---|---|---|---|
| Muggia et al. [55] | PLD 30 mg/m and BEV 15 mg/kg on cycles 2–7 (with option to continue) |
≤6 | 48 | Ongoing | Ongoing |
|
| |||||
| Pujade-Lauraine et al. [56] |
Arm1
PTX (80 mg/m2) d1, 8, 15 and 22 q28 or TPT (4 mg/m2) d1, 8, 15 q28 or PLD (40 mg/m2) d1 q28 |
≤6 | 166 | 12.6 | 3.4 |
|
Arm2
BEV 10 m/kg d1 q15 or 15 mg/kg d1 q21, PTX (80 mg/m2) d1, 8, 15 and 22 q28 or TPT (4 mg/m2) d1, 8, 15 q28 or PLD (40 mg/m2) d1 q28 |
135 | 30.9 | 6.7 | ||
|
| |||||
| Del Carmen et al. [57] | PLD (30 mg/m2) d1 q28, CBDCA (AUC5) d1 q28, Beva 10 mg/kg d1 q14 |
≥6 | 54 | 72.2 | 13.9 |
|
| |||||
| Steffensen et al. [58] | PAN 6 mg/kg d1, 15 q28/PLD 40 mg/m² day 1 q28 | ≤6 | 46 | 24.3 | 2.7–8.1 |
|
| |||||
| TRINOVA 2 [59] http://clinicaltrials.gov/show/NCT01281254 |
Arm 1
PLD 50 mg/m² d1 q28 and blinded AMG 386 15 mg/kg qw Arm 2 PLD 50 mg/m² d1 q28 and blinded AMG 386/placebo qw |
≤12 | Ongoing | Ongoing | Ongoing |
|
| |||||
| Boers-Sonderen et al. [60] | T 15–20 mg/m²/PLD 20–40 mg/mq | ALL |
20 |
3PR 9SD |
4.9 |
PFS: progression-free survival; PTX: paclitaxel; TPT: topotecan; T: temsirolimus; PAN: panitumumab; BEV: bevacizumab; RR: response rate; SEN: platinum-sensitive recurrentdisease; TRAB: trabectedin; q: every; d: day. *Statistically significant.